2023년 주요 7개국에서 원형 탈모증 진단을 받은 유병자는 약 170만 명으로 집계됐습니다. 이 중 미국이 35%, EU 4개국과 영국이 약 49%, 일본이 16%를 차지합니다. 원형 탈모증 시장은 꾸준히 성장하고 있으며, 2024년부터 2034년까지 연평균 성장률(CAGR)이 견조할 것으로 예상됩니다. 주요 7개국 전체에서 RINVOQ(우파다시티닙), 코아실륨(LH-8), 벤피키바트, 레즈페가르데스루킨(NKTR-358) 등 혁신적인 치료제의 출시에 힘입어 성장세를 견인할 것으로 예상됩니다.
주요 7개국의 원형 탈모증 시장 규모는 2023년 약 3억 7,900만 달러로, 2024년부터 2034년까지 예측 기간 동안 21.2%의 CAGR로 성장할 것으로 예상됩니다.
Eli Lilly and Company, Incyte Corporation, Pfizer, Sun Pharmaceuticals는 탈모증 시장의 주요 기업으로 미국(EU, 일본)에서는 OLUMIANT, 미국(EU, 일본)에서는 LITFULO, 미국(EU, 일본)에서는 LEQSELVI와 같은 승인된 치료제를 제공하고 있습니다.
이 보고서는 주요 7개국의 원형 탈모증 시장을 조사하여 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지의 시장 규모 예측, 미충족 의료 수요 등을 제공합니다.
DelveInsight's "Alopecia Areata - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of alopecia areata, historical and forecasted epidemiology, as well as the alopecia areata market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The alopecia areata market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM alopecia areata market size from 2020 to 2034. The report also covers alopecia areata treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Alopecia Areata overview
Alopecia areata is a prevalent autoimmune skin disorder that leads to hair loss on the scalp, face, and occasionally other parts of the body. It affects individuals of all ages, genders, and ethnic backgrounds, making it a widely inclusive condition in terms of its impact.
Alopecia areata has various forms, with the primary types being patchy alopecia areata, alopecia totalis, and alopecia universalis. Other clinical variants include persistent patchy, diffuse, and ophiasis alopecia areata. It is considered a "polygenic disease" due to its genetic predisposition and multifactorial inheritance pattern.
Alopecia areata is an autoimmune condition that targets hair follicles, causing sudden hair loss, often in small patches that can expand into larger bald areas. Hair loss may also affect other areas, such as eyelashes, eyebrows, or the beard (in men), typically occurring without accompanying redness, rashes, or scarring on the affected skin.
Alopecia areata is caused by various risk factors, including nutritional deficiencies, systemic illnesses like autoimmune or thyroid disorders, and stress, which disrupts immune function. Genetic predisposition, environmental triggers such as infections or allergens, and certain medications can also contribute, with family history often increasing susceptibility to the condition.
Alopecia Areata diagnosis
Alopecia areata's differential diagnosis includes non-scarring hair loss conditions like tinea capitis, trichotillomania, and telogen effluvium. Comorbidities may include autoimmune diseases, atopic conditions, and psychiatric disorders, with age influencing prevalence. Screening involves tests like hair pull, trichogram, dermatoscopy, and biopsy to assess symptoms and clinical signs.
Alopecia Areata treatment
Alopecia areata treatments range from mild options like topical corticosteroids to systemic corticosteroids for severe cases. Other therapies include topical immunotherapy, methotrexate, cyclosporine, OX40L, and JAK inhibitors. Adjuncts like minoxidil, vitamin D, and zinc offer variable results, while phototherapy and platelet-rich plasma show limited success with relapses.
As the market is derived using a patient-based model, the alopecia areata epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Alopecia Areata, Diagnosed Prevalent Cases of Alopecia Areata, Gender-specific Diagnosed Prevalent Cases of Alopecia Areata, Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata, and Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the alopecia areata report encloses a detailed analysis of alopecia areata marketed drugs and mid to late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the alopecia areata clinical trial details, expressive pharmacological action, agreements and collaborations and approval, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
OLUMIANT (Baricitinib): Eli Lilly and Company/Incyte Corporation
OLUMIANT is a selective and reversible JAK inhibitor that targets the cytokine signaling pathway associated with alopecia areata. It works by inhibiting the activation of ATPase on JAK, blocking signal transmission to cells via the Signal Transducer and Activator of Transcription (STAT) pathway. This mechanism disrupts inflammation and immune responses involved in the condition. OLUMIANT, acting as a JAK inhibitor, has received regulatory approval in the US, EU, and Japan for the treatment of severe alopecia areata.
LITFULO (Ritlecitinib): Pfizer
LITFULO (ritlecitinib), developed by Pfizer, is an innovative FDA-approved oral treatment for severe alopecia areata, an autoimmune disorder causing significant hair loss. It works by targeting JAK3 and TEC inhibitors to disrupt immune pathways responsible for hair follicle destruction. LITFULO has been approved for use in the US, EU, and Japan, addressing the needs of individuals aged 12 and older with severe forms of the condition. It also received breakthrough designation, highlighting its potential to transform alopecia areata treatment.
LEQSELVI (Deuruxolitinib, CTP 543): Sun Pharmaceuticals
LEQSELVI (Deuruxolitinib), developed by Sun Pharmaceutical Industries, is an FDA-approved oral treatment for severe alopecia areata in adults. It works by inhibiting JAK1 and JAK2, targeting immune pathways that contribute to hair loss in the condition. LEQSELVI is taken once daily and has received breakthrough and fast track designation for alopecia areata. This approval provides a new treatment option for individuals with severe alopecia areata, offering hope for those affected by this autoimmune disorder.
Emerging Drugs
RINVOQ (Upadacitinib): AbbVie
RINVOQ (upadacitinib), a JAK1-specific oral inhibitor, shows promise for alopecia areata treatment, despite being primarily approved for rheumatoid arthritis and atopic dermatitis. Clinical studies indicate significant hair regrowth and improved quality of life. Currently in Phase III, RINVOQ is projected for alopecia areata approval by 2027.
Bempikibart (ADX-914): Q32 Bio
Bempikibart (ADX-914) is a fully human antibody that targets the IL-7 Receptor Alpha subunit (IL-7Ra) and Thymic Stromal Lymphopoietin (TSLP), aiming to regulate immune function in autoimmune diseases. Currently in Phase II trials for alopecia areata, both IL-7 and TSLP pathways are linked to T-cell-mediated processes in autoimmune conditions. Q32 Bio has completed enrollment for the Phase II trial.
Amlitelimab (SAR-445229): Sanofi
Amlitelimab (SAR-445229) is a monoclonal antibody targeting OX40L, a molecule that activates T cells driving autoimmune responses. By blocking the OX40-OX40L pathway, it reduces inflammation and regulates the immune system without widespread immunosuppression. Currently in Phase II trials for alopecia areata, it shows potential as a targeted, effective alternative to traditional immunosuppressive therapies.
Drug Class Insights
Alopecia areata treatment primarily involves corticosteroids as the first-line therapy, often combined with immunosuppressants like methotrexate or azathioprine for patients who do not respond adequately.
Emerging therapies include RINVOQ (Upadacitinib), coacillium (LH-8), and STS01.
RINVOQ (Upadacitinib) is developed by AbbVie, is an oral JAK1 selective inhibitor in Phase III trials for severe alopecia areata, with participant recruitment ongoing. The trial is expected to conclude by March 2028, targeting immune pathways involved in hair loss.
Coacillium (LH-8) is developed by Legacy Healthcare, is the only botanical drug candidate for alopecia areata. As a cutaneous solution, it modulates immune-inflammatory pathways and has completed Phase II/III trials under the RAAINBOW study, targeting hair loss mechanisms.
STS01 is developed by Soterios, is a small-molecule topical cream for mild-to-moderate alopecia areata. Completing Phase II trials, it targets cytokines to modulate immune responses, offering a non-steroidal, safe alternative to JAK inhibitors and potential standard treatment for patchy alopecia areata.
Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss, often starting as patchy bald spots on the scalp but potentially affecting other hair-bearing areas. The immune system attacks hair follicles, disrupting growth cycles. The condition can range from localized patches to complete hair loss (alopecia totalis or universalis). Genetic and environmental factors contribute to its onset. Besides physical effects, alopecia areata significantly impacts emotional well-being and quality of life.
The treatment landscape for alopecia areata has evolved to incorporate a comprehensive approach, combining medications with supportive care. The market offers a range of therapies, including corticosteroids, immunosuppressants, immunomodulators, and topical sensitizers or irritants. Corticosteroids remain central for their anti-inflammatory properties, reducing immune attacks on hair follicles, while immunosuppressants and immunomodulators are used in more severe or resistant cases to regulate the immune system and prevent further hair loss.
Topical sensitization therapies, like diphencyprone, induce a mild allergic reaction to divert the immune response from hair follicles. Similarly, topical irritation therapies trigger irritation to stimulate hair regrowth. Minoxidil, a vasodilator, promotes blood flow to hair follicles and is often used off-label for alopecia areata. Dithranol, less commonly used, creates controlled inflammation to alter immune responses and encourage regrowth, primarily for patchy alopecia areata as part of sensitization therapy.
Some drugs are currently approved and available for the treatment of alopecia areata, reflecting the focus on immune modulation therapies. Key options include OLUMIANT, a small molecule co-developed by Eli Lilly and Company and Incyte Corporation, and LITFULO, a JAK3 and TEC kinase inhibitors offered by Pfizer. LEQSELVI, JAK1 and JAK2 inhibitors developed by Sun Pharmaceuticals.
There is a significant need for new treatments for alopecia areata, as existing therapies often fall short of fully managing the condition. Innovative drug development could provide more effective options for patients. Several promising drugs are currently in the pipeline, including RINVOQ (Upadacitinib), coacillium (LH-8), and STS01, among others.
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034.
Alopecia Areata Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for alopecia areata.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on alopecia areata evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Brigham and Women's Hospital, the US, Atrium Health Wake Forest Baptist, the US, Carver College of Medicine, the US, Charite - Universitatsmedizin Berlin, Germany, Centre hospitalier universitaire de Nantes, France, University of Bologna, Italy, International University of Catalonia (UIC Barcelona), Spain, University of Bradford, the UK, Kyorin University School of Medicine, Japan, among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or alopecia areata market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Physician's View
As per the KOLs from the US, early detection is pivotal in improving patient outcomes and enhancing healthcare efficiency. It enables access to a broader range of treatment options, including less aggressive therapies, which greatly enhance a patient's quality of life. Timely diagnosis is strongly associated with higher survival rates, as it prevents the disease from advancing to more severe stages.
As per the KOLs from Germany, recent studies have highlighted the critical role of CD8+NKG2D+ T cells as key effectors in the pathogenesis of alopecia areata. Both mouse and human studies have shown gene expression profiles indicative of cytotoxic T cell infiltration, heightened IFN-? responses, and upregulation of ?-chain cytokines like IL-2 and IL-15, which support the activation and persistence of these effector T cells. Additionally, Vd1+ T cells with pro-inflammatory properties were significantly enriched in the supra bulbar and bulbar regions of affected hair follicles, providing further insight into the immunological mechanisms driving this disease.
As per the KOLs from Japan, the understanding of alopecia areata in Japan remains limited due to scarce epidemiological data. To address this gap, it is crucial to thoroughly investigate the prevalence and severity of the condition within the Japanese population. This insight will be pivotal in shaping future research initiatives and guiding the development of tailored treatment options for affected patients.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based on their ability to improve atrial and ventricular dimension/function and ability to regulate heart rate.
Further, the therapies' safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Eli Lilly OLUMIANT Support Services
Eli Lilly's OLUMIANT companion in care team collaborates with doctors, specialty pharmacies, and insurance providers to streamline the process of verifying coverage, exploring pharmacy options, and assisting with savings enrollment. Upon receiving the prescription, the insurance company evaluates coverage and cost, coordinating with the specialty pharmacy. The pharmacy handles insurance approval, medication preparation, and patient communication for payment and delivery. For eligible patients, the co-pay program offers the opportunity to pay as little as USD 5 for a 30-day supply, or USD 25 if insurance doesn't cover the medication, reducing out-of-pocket expenses.
The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Alopecia Areata report insights
Alopecia Areata report key strengths
Alopecia Areata report assessment
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
11.10.. IMG-007: Inmagene